Purpose of Technology
The second-wave direct-acting antivirals (DAAs) are prescribed to treat chronic hepatitis C with the objective of achieving sustained viral response and preventing harmful liver damage. These agents were developed to address the issues associated with pegylated interferon, ribavirin, and previously approved DAAs, including lack of response and relapse, resistance, poor safety profile, and burdensome treatment regimen. Second-wave DAA agents include simeprevir, sofosbuvir, and the combination of ledipasvir and sofosbuvir.
Does fixed-dose ledipasvir-sofosbuvir improve rates of viral response in patients with chronic HCV who have been previously treated with standard care and in those who are treatment naïve?
Is fixed-dose ledipasvir-sofosbuvir effective for all HCV genotypes?
Is fixed-dose ledipasvir-sofosbuvir safe?
Have definitive patient selection criteria been established for fixed-dose ledipasvir-sofosbuvir?
If you have a Hayes login, click here to view the full report on the Knowledge Center.